Steven M Paul
CIK 1237564 · CSO and President of R&D · last filed 2026-10-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SAGE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1325 BOYLSTON STREET, SUITE 401
BOSTON, MA 02215
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RAPP | Director | 555,022 | $27.73 | $15.39M | $2.00M | 4 | 2026-10-22 |
| SPTX | Director | 863,031 | $21.79 | $18.80M | $0 | 1 | 2026-05-04 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | CSO and President of R&D | 0 | $329.83 | $0 | -$29.76M | 12 | 2024-03-18 |
| Sage Therapeutics, Inc. (SAGE) Delisted | Director | 303,377 | $8.68 | $2.63M | -$37.05M | 29 | 2024-01-04 |
| ALNY | Director | 10,799 | $225.34 | $2.43M | -$8.47M | 16 | 2022-04-05 |
| VYGR | Chief Executive Officer | 872,351 | $1.75 | $1.53M | $140.7K | 7 | 2021-06-04 |
| SIGMA ALDRICH CORP (SIAL) Delisted | Director | 0 | — | — | $0 | 19 | 2015-11-19 |
| LLY | EVP, Science and Technology | 39,476 | $1279.10 | $50.49M | -$2.35M | 15 | 2010-02-03 |
Recent Filings · Page 10 of 11
103 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-01-29 | LLY | Grant (A) | +44,256 | $2.25M | EDGAR |
| 2008-01-02 | SIGMA ALDRICH CORP (SIAL) Delisted | Grant (A) | +1,200 | $0 | EDGAR |
| 2007-08-01 | LLY | Disc (I) | −3,163 | -$171.1K | EDGAR |
| 2007-06-04 | LLY | Tax (F) | −1,226 | -$71.9K | EDGAR |
| 2007-05-23 | LLY | Mixed | +4,573 | -$197.9K | EDGAR |
| 2007-05-17 | LLY | Mixed | +92 | -$4.1K | EDGAR |
| 2007-03-13 | LLY | Sell (S) | −7,289 | -$381.9K | EDGAR |
| 2007-02-14 | LLY | Mixed | −7,290 | -$396.4K | EDGAR |
| 2007-02-13 | SIGMA ALDRICH CORP (SIAL) Delisted | Grant (A) | +1,200 | $0 | EDGAR |
| 2007-02-12 | LLY | Sell (S) | −10,092 | -$548.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.